Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
49
MKKGY Quote, Financials, Valuation and Earnings
Last price:
$28.96
Seasonality move
:
0.88%
Day range:
$28.53 - $28.99
52-week range:
$24.32 - $31.00
Dividend yield:
1.73%
P/E ratio:
19.21x
P/S ratio:
2.68x
P/B ratio:
6.23x
Volume:
88.1K
Avg. volume:
75.3K
1-year change:
-1.93%
Market cap:
$63B
Revenue:
$22.9B
EPS (TTM):
$1.51
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MKKGY
Merck KGaA
|
$6.2B | $0.49 | 7.93% | 50.37% | $34.04 |
|
BAYRY
Bayer AG
|
$13.4B | $0.16 | 11.17% | 16.01% | $13.91 |
|
BNTX
BioNTech SE
|
$963.1M | -$0.10 | 94.57% | -31.62% | $139.76 |
|
IFRX
InflaRx NV
|
$30.9K | -$0.17 | -74.55% | -69.76% | $10.46 |
|
IMTX
Immatics NV
|
$10.9M | -$0.47 | -81.87% | -704.25% | $19.13 |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MKKGY
Merck KGaA
|
$28.96 | $34.04 | $63B | 19.21x | $0.50 | 1.73% | 2.68x |
|
BAYRY
Bayer AG
|
$13.41 | $13.91 | $52.7B | -- | $0.03 | 0.23% | 1.04x |
|
BNTX
BioNTech SE
|
$106.62 | $139.76 | $26.8B | 191.55x | $0.00 | 0% | 7.25x |
|
IFRX
InflaRx NV
|
$0.89 | $10.46 | $60.6M | -- | $0.00 | 0% | 276.51x |
|
IMTX
Immatics NV
|
$9.63 | $19.13 | $1.2B | 42.21x | $0.00 | 0% | 12.86x |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MKKGY
Merck KGaA
|
29.49% | -0.053 | 25.12% | 0.76x |
|
BAYRY
Bayer AG
|
57.27% | -0.191 | 142.34% | 0.55x |
|
BNTX
BioNTech SE
|
1.31% | 1.308 | 1.22% | 6.78x |
|
IFRX
InflaRx NV
|
2.1% | -0.262 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 2.067 | 1.86% | 6.97x |
|
MDGEF
Medigene AG
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MKKGY
Merck KGaA
|
$3.8B | $1.4B | 7.45% | 10.11% | 22.9% | $579.8M |
|
BAYRY
Bayer AG
|
$6.3B | $655.6M | -0.4% | -0.91% | 5.81% | $616.1M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | -- | -- |
Merck KGaA vs. Competitors
-
Which has Higher Returns MKKGY or BAYRY?
Bayer AG has a net margin of 16.89% compared to Merck KGaA's net margin of -9.93%. Merck KGaA's return on equity of 10.11% beat Bayer AG's return on equity of -0.91%.
Company Gross Margin Earnings Per Share Invested Capital MKKGYMerck KGaA60.42% $0.48 $48.3B BAYRYBayer AG55.41% -$0.29 $81.5B -
What do Analysts Say About MKKGY or BAYRY?
Merck KGaA has a consensus price target of $34.04, signalling upside risk potential of 17.54%. On the other hand Bayer AG has an analysts' consensus of $13.91 which suggests that it could grow by 3.75%. Given that Merck KGaA has higher upside potential than Bayer AG, analysts believe Merck KGaA is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings MKKGYMerck KGaA1 0 0 BAYRYBayer AG1 1 0 -
Is MKKGY or BAYRY More Risky?
Merck KGaA has a beta of 0.973, which suggesting that the stock is 2.665% less volatile than S&P 500. In comparison Bayer AG has a beta of 0.677, suggesting its less volatile than the S&P 500 by 32.326%.
-
Which is a Better Dividend Stock MKKGY or BAYRY?
Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.73%. Bayer AG offers a yield of 0.23% to investors and pays a quarterly dividend of $0.03 per share. Merck KGaA pays 24.48% of its earnings as a dividend. Bayer AG pays out 4.24% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MKKGY or BAYRY?
Merck KGaA quarterly revenues are $6.2B, which are smaller than Bayer AG quarterly revenues of $11.3B. Merck KGaA's net income of $1B is higher than Bayer AG's net income of -$1.1B. Notably, Merck KGaA's price-to-earnings ratio is 19.21x while Bayer AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.68x versus 1.04x for Bayer AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MKKGYMerck KGaA2.68x 19.21x $6.2B $1B BAYRYBayer AG1.04x -- $11.3B -$1.1B
-
Which has Higher Returns MKKGY or BNTX?
BioNTech SE has a net margin of 16.89% compared to Merck KGaA's net margin of -1.89%. Merck KGaA's return on equity of 10.11% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital MKKGYMerck KGaA60.42% $0.48 $48.3B BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About MKKGY or BNTX?
Merck KGaA has a consensus price target of $34.04, signalling upside risk potential of 17.54%. On the other hand BioNTech SE has an analysts' consensus of $139.76 which suggests that it could grow by 31.08%. Given that BioNTech SE has higher upside potential than Merck KGaA, analysts believe BioNTech SE is more attractive than Merck KGaA.
Company Buy Ratings Hold Ratings Sell Ratings MKKGYMerck KGaA1 0 0 BNTXBioNTech SE14 5 0 -
Is MKKGY or BNTX More Risky?
Merck KGaA has a beta of 0.973, which suggesting that the stock is 2.665% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.488, suggesting its more volatile than the S&P 500 by 48.755%.
-
Which is a Better Dividend Stock MKKGY or BNTX?
Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.73%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 24.48% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MKKGY or BNTX?
Merck KGaA quarterly revenues are $6.2B, which are larger than BioNTech SE quarterly revenues of $1.8B. Merck KGaA's net income of $1B is higher than BioNTech SE's net income of -$33.5M. Notably, Merck KGaA's price-to-earnings ratio is 19.21x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.68x versus 7.25x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MKKGYMerck KGaA2.68x 19.21x $6.2B $1B BNTXBioNTech SE7.25x 191.55x $1.8B -$33.5M
-
Which has Higher Returns MKKGY or IFRX?
InflaRx NV has a net margin of 16.89% compared to Merck KGaA's net margin of -51538.49%. Merck KGaA's return on equity of 10.11% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital MKKGYMerck KGaA60.42% $0.48 $48.3B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About MKKGY or IFRX?
Merck KGaA has a consensus price target of $34.04, signalling upside risk potential of 17.54%. On the other hand InflaRx NV has an analysts' consensus of $10.46 which suggests that it could grow by 1068.62%. Given that InflaRx NV has higher upside potential than Merck KGaA, analysts believe InflaRx NV is more attractive than Merck KGaA.
Company Buy Ratings Hold Ratings Sell Ratings MKKGYMerck KGaA1 0 0 IFRXInflaRx NV5 2 0 -
Is MKKGY or IFRX More Risky?
Merck KGaA has a beta of 0.973, which suggesting that the stock is 2.665% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.457, suggesting its more volatile than the S&P 500 by 45.659%.
-
Which is a Better Dividend Stock MKKGY or IFRX?
Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.73%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 24.48% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MKKGY or IFRX?
Merck KGaA quarterly revenues are $6.2B, which are larger than InflaRx NV quarterly revenues of $27.8K. Merck KGaA's net income of $1B is higher than InflaRx NV's net income of -$14.3M. Notably, Merck KGaA's price-to-earnings ratio is 19.21x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.68x versus 276.51x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MKKGYMerck KGaA2.68x 19.21x $6.2B $1B IFRXInflaRx NV276.51x -- $27.8K -$14.3M
-
Which has Higher Returns MKKGY or IMTX?
Immatics NV has a net margin of 16.89% compared to Merck KGaA's net margin of -974.45%. Merck KGaA's return on equity of 10.11% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital MKKGYMerck KGaA60.42% $0.48 $48.3B IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About MKKGY or IMTX?
Merck KGaA has a consensus price target of $34.04, signalling upside risk potential of 17.54%. On the other hand Immatics NV has an analysts' consensus of $19.13 which suggests that it could grow by 98.6%. Given that Immatics NV has higher upside potential than Merck KGaA, analysts believe Immatics NV is more attractive than Merck KGaA.
Company Buy Ratings Hold Ratings Sell Ratings MKKGYMerck KGaA1 0 0 IMTXImmatics NV9 0 0 -
Is MKKGY or IMTX More Risky?
Merck KGaA has a beta of 0.973, which suggesting that the stock is 2.665% less volatile than S&P 500. In comparison Immatics NV has a beta of 1.359, suggesting its more volatile than the S&P 500 by 35.865%.
-
Which is a Better Dividend Stock MKKGY or IMTX?
Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.73%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 24.48% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MKKGY or IMTX?
Merck KGaA quarterly revenues are $6.2B, which are larger than Immatics NV quarterly revenues of $6.1M. Merck KGaA's net income of $1B is higher than Immatics NV's net income of -$59.1M. Notably, Merck KGaA's price-to-earnings ratio is 19.21x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.68x versus 12.86x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MKKGYMerck KGaA2.68x 19.21x $6.2B $1B IMTXImmatics NV12.86x 42.21x $6.1M -$59.1M
-
Which has Higher Returns MKKGY or MDGEF?
Medigene AG has a net margin of 16.89% compared to Merck KGaA's net margin of --. Merck KGaA's return on equity of 10.11% beat Medigene AG's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MKKGYMerck KGaA60.42% $0.48 $48.3B MDGEFMedigene AG-- -- -- -
What do Analysts Say About MKKGY or MDGEF?
Merck KGaA has a consensus price target of $34.04, signalling upside risk potential of 17.54%. On the other hand Medigene AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Merck KGaA has higher upside potential than Medigene AG, analysts believe Merck KGaA is more attractive than Medigene AG.
Company Buy Ratings Hold Ratings Sell Ratings MKKGYMerck KGaA1 0 0 MDGEFMedigene AG0 0 0 -
Is MKKGY or MDGEF More Risky?
Merck KGaA has a beta of 0.973, which suggesting that the stock is 2.665% less volatile than S&P 500. In comparison Medigene AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MKKGY or MDGEF?
Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.73%. Medigene AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 24.48% of its earnings as a dividend. Medigene AG pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MKKGY or MDGEF?
Merck KGaA quarterly revenues are $6.2B, which are larger than Medigene AG quarterly revenues of --. Merck KGaA's net income of $1B is higher than Medigene AG's net income of --. Notably, Merck KGaA's price-to-earnings ratio is 19.21x while Medigene AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.68x versus -- for Medigene AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MKKGYMerck KGaA2.68x 19.21x $6.2B $1B MDGEFMedigene AG-- -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
